Clinical trials: Advanced Pleural Malignant Mesothelioma
Advanced Malignant Mesothelioma, Epithelial Mesothelioma
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma
This randomized phase II trial is to see if combination chemotherapy works better with or without bevacizumab in treating patients who have malignant mesothelioma.
- Conditions
- Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Localized Malignant Mesothelioma, Recurrent Malignant Mesothelioma
- Trial name
- NCT00027703
- Testing
- gemcitabine hydrochloride, cisplatin, bevacizumab
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Cancer, Advanced Solid Tumor
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens.
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis
- Trial name
- NCT06362369
- Testing
- Alintegimod, Ipilimumab, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 126 people
- Sponsor
- 7 Hills Pharma, LLC
Malignant Mesothelioma, Metastatic Malignant Solid Tumor
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
This is a Phase 1/2, open-label, multicenter, FIH study to evaluate the safety, tolerability, recommended Phase 2 dose (RP2D), PK/PD, and preliminary anti-tumor activity of ISM6331 in participants with advanced or metastatic…
- Conditions
- Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor
- Trial name
- NCT06566079
- Testing
- ISM6331
- Where
- 10 sites in United States, China
- Volunteers
- 160 people
- Sponsor
- InSilico Medicine Hong Kong Limited
Advanced Esophageal Cancers, Primary Small Cell Lung Cancers
Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies
Background: Previously we have demonstrated induction of tumor antigen and tumor suppressor gene expression in lung cancer cells following exposure to the DNA demethylating agent, Decitabine (DAC).
- Conditions
- Advanced Esophageal Cancers, Primary Small Cell Lung Cancers, Non-Small-Cell Lung Carcinoma, Pleural Mesotheliomas
- Trial name
- NCT00037817
- Testing
- Decitabine, Depsipeptide, Celecoxib
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Pleural Mesothelioma
Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma
The main objective of the trial is to document the progression free survival (PFS) in advanced or metastatic malignant pleural mesothelioma patients treated with NGR-hTNF as single agent.
- Trial name
- NGR010 (NCT00484276)
- Testing
- NGR-hTNF
- Where
- 4 sites in Italy
- Volunteers
- 57 people
- Sponsor
- AGC Biologics S.p.A.
Renal Cell Cancer, Castrate Resistant Prostate Cancer
TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
The goal of this clinical trial is to evaluate TT-10, TT-4 and TT-10 + TT-4, (Dual Blockade) in participants with advanced selected solid tumors, who have failed or are not eligible for standard of care.
- Conditions
- Renal Cell Cancer, Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer, Pleural Mesothelioma Malignant
- Trial name
- NCT04969315
- Testing
- TT-10, TT-4
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Portage Biotech
Neoplasms, Prostatic Neoplasms, Castration-Resistant
HTL0039732 in Participants With Advanced Solid Tumours
The purpose of this trial is to evaluate a new drug, HTL0039732, that will be administered on its own (as a monotherapy) and in combination with atezolizumab or with other approved anti-cancer therapies, in participants with…
- Conditions
- Neoplasms, Prostatic Neoplasms, Castration-Resistant, Stomach Neoplasms, Esophageal Neoplasms
- Trial name
- NCT05944237
- Testing
- HTL0039732 Capsules, HTL0039732 Capsules or HTL0039732 tablets and atezolizumab infusion
- Where
- 6 sites in United Kingdom
- Volunteers
- 150 people
- Sponsor
- Cancer Research UK
Malignant Mesothelioma
Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma
RATIONALE: Patient abstract not available PURPOSE: Patient abstract not available
- Trial name
- NCT00004033
- Testing
- liposomal NDDP, therapeutic thoracoscopy
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- NYU Langone Health
Advanced Cancer, Metastatic Cancer
A Study of LY3023414 in Participants With Advanced Cancer
The purpose of this study is to find a recommended dose level and schedule of dosing LY3023414 that can safely be taken by participants with advanced or metastatic cancer.
- Conditions
- Advanced Cancer, Metastatic Cancer, Non-Hodgkin's Lymphoma, Metastatic Breast Cancer
- Trial name
- NCT01655225
- Testing
- LY3023414, Midazolam, Fulvestrant
- Where
- 8 sites in United States, Italy and 1 more
- Volunteers
- 156 people
- Sponsor
- Eli Lilly and Company
Malignant Mesothelioma
Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma
Current therapies for advanced Mesothelioma provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of advanced Mesothelioma.
- Trial name
- NCT00003508
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Burzynski Research Institute
Advanced Malignant Mesothelioma, Extensive Stage Small Cell Lung Cancer
Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body
This pilot clinical trial studies the side effects of cryotherapy (cryoablation [CA]) in treating patients with lung cancer. Cryotherapy kills cancer cells by freezing them.
- Conditions
- Advanced Malignant Mesothelioma, Extensive Stage Small Cell Lung Cancer, Lung Metastases, Recurrent Malignant Mesothelioma
- Trial name
- NCT01325753
- Testing
- cryotherapy, quality-of-life assessment
- Sponsor
- Wake Forest University Health Sciences
Malignant Pleural Mesothelioma, Advanced
Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma
The purpose of this study is to evaluate the efficacy and safety of Oncolytic Adenovirus(H101) combined with PD-1 inhibitor in patients with advanced malignant pleural mesothelioma who have previously been resistant to advanced…
- Trial name
- NCT06031636
- Testing
- Oncolytic Adenovirus H101, Programmed death receptor-1 inhibitor
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Tianjin Medical University Second Hospital
Solid Tumor Malignancies, Malignant Mesothelioma (MM)
Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors
This study is to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of the TEAD inhibitor TYK-01054 capsules in patients with locally advanced or metastatic advanced solid tumors
- Trial name
- NCT07282873
- Testing
- TYK-01054
- Where
- China
- Volunteers
- 219 people
- Sponsor
- TYK Medicines, Inc
Mesothelioma
Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Pembrolizumab is a new type of drug for mesothelioma (immunotherapy). Laboratory tests show that this drug works by helping improve the body's immune response to help fight cancer.
- Trial name
- NCT02784171
- Testing
- Cisplatin, Pemetrexed, Pembrolizumab
- Where
- 57 sites in Canada, France and 1 more
- Volunteers
- 520 people
- Sponsor
- Canadian Cancer Trials Group
Malignant Mesothelioma
Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if cisplatin is more effective with or without pemetrexed disodium for malignant…
- Trial name
- NCT00005636
- Testing
- cisplatin, pemetrexed disodium
- Where
- 3 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Carcinoma, Fallopian Tube Carcinoma
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
This is a first-in-human, open-label, multi-center, Phase 1, dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose…
- Conditions
- Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma, Endometrial Cancer
- Trial name
- NCT06299163
- Testing
- NM32-2668
- Where
- 11 sites in United States
- Volunteers
- 11 people
- Sponsor
- Numab Therapeutics AG
Malignant Pleural Mesothelioma, Advanced
Safety and Preliminary Antitumor Activity of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma
This Phase 1a, open-label, dose-escalation study evaluates the safety, tolerability, and preliminary antitumor activity of ivonescimab in combination with pemetrexed and platinum-based chemotherapy as first-line treatment for…
- Trial name
- NCT07885306
- Testing
- Ivonescimab Combined With Chemotherapy
- Where
- 4 sites in China
- Volunteers
- 9 people
- Sponsor
- Ruijin Hospital
NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC)
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine…
- Conditions
- NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus
- Trial name
- NCT07277413
- Testing
- IDE892, IDE397
- Where
- 23 sites in United States
- Volunteers
- 260 people
- Sponsor
- IDEAYA Biosciences
Breast Cancer, Glioblastoma
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
This is a Phase 1 dose-escalation study of PRT3645, a Cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor, in patients with advanced or metastatic solid tumors.
- Conditions
- Breast Cancer, Glioblastoma, Head and Neck Squamous Cell Carcinoma, Malignant Mesothelioma
- Trial name
- NCT05538572
- Testing
- PRT3645
- Where
- 13 sites in United States, Singapore
- Volunteers
- 22 people
- Sponsor
- Prelude Therapeutics Incorporated
Unresectable Pleural Mesothelioma
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab +…
- Trial name
- eVOLVE-Meso (NCT06097728)
- Testing
- Volrustomig, Pemetrexed, Carboplatin
- Where
- 151 sites in United States, Australia and 19 more
- Volunteers
- 863 people
- Sponsor
- AstraZeneca